The Allurion Balloon is a regulated health product that bears the CE marking in accordance with this regulation. The indications for use of the Allurion Gastric Balloon System are to promote weight loss in individuals living with excess weight or …

Jan 21, 2025 · The Allurion Program features the Allurion gastric balloon, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for clinicians, and the Allurion Connected Scale and Health Tracker devices.

Feb 9, 2023 · This press release relates to a proposed business combination between Allurion, Compute Health and Allurion Technologies Holdings, Inc., a wholly-owned subsidiary of Allurion which will be the publicly-listed Company following the …

Dec 24, 2024 · Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

The Allurion Gastric Balloon and Weight-Loss Program combines medical, digital, and nutritional approaches to help weight loss and form lifelong healthy habits.

BOSTON, MA – July 25, 2023 – Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, is pleased to announce two major additions to the team.

Oct 11, 2023 · NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon.

At Allurion, we seek to end obesity globally, helping our patients to live fuller, longer lives. We aim to be the catalyst for weight loss for life. A lasting weight loss program that will guide your weight loss for life.

Jan 23, 2025 · Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.

Jan 14, 2025 · Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at ...